James Richard Porter Sells 30,000 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 30,000 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $88.53, for a total value of $2,655,900.00. Following the completion of the transaction, the chief executive officer directly owned 324,879 shares in the company, valued at approximately $28,761,537.87. This represents a 8.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

James Richard Porter also recently made the following trade(s):

• On Monday, May 4th, James Richard Porter sold 30,000 shares of Nuvalent stock. The shares were sold at an average price of $101.69, for a total value of $3,050,700.00.
• On Monday, April 6th, James Richard Porter sold 30,000 shares of Nuvalent stock. The shares were sold at an average price of $103.77, for a total value of $3,113,100.00.

Nuvalent Stock Up 0.1%

Shares of NUVL stock opened at $123.45 on Friday. Nuvalent, Inc. has a twelve month low of $71.13 and a twelve month high of $123.62. The company has a market cap of $9.75 billion, a P/E ratio of -20.37 and a beta of 1.15. The business has a fifty day simple moving average of $103.86 and a 200 day simple moving average of $103.31.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same period last year, the company posted ($1.18) earnings per share. As a group, equities research analysts anticipate that Nuvalent, Inc. will post -5.74 earnings per share for the current fiscal year.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, which provides a cash-out premium and is the main reason the stock is up. Article Title
• Positive Sentiment: Market and Reuters coverage say the deal supports GSK’s oncology rebuild, suggesting the transaction is strategically credible and likely to close at the announced terms. Article Title
• Neutral Sentiment: Several law firms have launched investigations into whether the sale price and process were fair to shareholders, creating headline noise but not changing the announced deal. Article Title
• Neutral Sentiment: Multiple brokers downgraded Nuvalent to hold after the acquisition announcement, but their updated targets remain near the deal price, limiting incremental downside. Article Title
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly weigh on sentiment by signaling reduced insider exposure. Article Title

Institutional Trading of Nuvalent

A number of hedge funds have recently bought and sold shares of NUVL. GAMMA Investing LLC increased its position in Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Nuvalent by 141.3% in the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after buying an additional 195 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Nuvalent in the third quarter worth $38,000. NBC Securities Inc. purchased a new stake in Nuvalent in the fourth quarter worth $125,000. Finally, KBC Group NV increased its position in Nuvalent by 24.1% in the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after buying an additional 297 shares during the last quarter. 97.26% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NUVL. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $124.00 target price (up from $116.00) on shares of Nuvalent in a research note on Tuesday. HC Wainwright cut Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 target price for the company. in a research note on Tuesday. Wedbush cut Nuvalent from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $125.00 to $124.00 in a research note on Tuesday. Raymond James Financial cut Nuvalent from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Finally, Canaccord Genuity Group lowered Nuvalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $131.15.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.